98%
921
2 minutes
20
Background: A combination of plasma phospho-tau (p-tau), amyloid beta (Aβ)-positron emission tomography (PET), brain magnetic resonance imaging, cognitive function tests, and other biomarkers might predict future cognitive decline. This study aimed to investigate the efficacy of combining these biomarkers in predicting future cognitive stage transitions within 3 years.
Methods: Among the participants in the Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease (KBASE-V) study, 49 mild cognitive impairment (MCI) and 113 cognitively unimpaired (CU) participants with Aβ-PET and brain imaging data were analyzed.
Results: Older age, increased plasma p-tau181, Aβ-PET positivity, and decreased semantic fluency were independently associated with cognitive stage transitions. Combining age, p-tau181, the Centiloid scale, semantic fluency, and hippocampal volume produced high predictive value in predicting future cognitive stage transition (area under the curve = 0.879).
Conclusions: Plasma p-tau181 and Centiloid scale alone or in combination with other biomarkers, might predict future cognitive stage transition in non-dementia patients.
Highlights: -Plasma p-tau181 and Centiloid scale might predict future cognitive stage transition. -Combining them or adding other biomarkers increased the predictive value. -Factors that independently associated with cognitive stage transition were demonstrated.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12009171 | PMC |
http://dx.doi.org/10.1002/alz.13054 | DOI Listing |
Alzheimers Dement
September 2025
Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA.
Introduction: Mild cognitive impairment (MCI) represents a transitional stage between normal aging and dementia. We investigate associations among cardiovascular and metabolic disorders (hypertension, diabetes mellitus, and hyperlipidemia) and diagnosis (normal; amnestic [aMCI]; and non-amnestic [naMCI]).
Methods: Multinomial logistic regressions of participant data (N = 8737; age = 70.
Br J Cancer
September 2025
Centre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, E1 1HH, UK.
Background: Multi-cancer detection (MCED) blood tests have the potential to screen for early-stage cancers. Understanding how people experience an MCED cancer signal result is vital prior to any future implementation. We explored experiences in a trial context.
View Article and Find Full Text PDFEncephale
September 2025
Département de psychiatrie de l'adolescent et du jeune adulte, institut mutualiste Montsouris, 42, boulevard Jourdan, Paris, France; UVSQ, Inserm U1178, PsyDev, CESP université Paris-Saclay, Villejuif, France; Université Paris-Cité, Paris, France.
The body of knowledge on trauma is rapidly expanding. Since 2022, the WHO has been calling for the history of adversity to be systematically taken into account when assessing the state of health of all individuals. But at this stage, our understanding of the precise mechanisms of complex trauma remains incomplete.
View Article and Find Full Text PDFJMIR Res Protoc
September 2025
Department of Psychiatry, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Republic of Korea.
Background: Autism spectrum disorder (ASD) and social communication disorder (SCD) are neurodevelopmental disorders characterized by deficits in social communication that hinder social adaptation, with limited pharmacological options for therapy owing to the absence of identified biomarkers. Individuals with ASD or SCD require lifelong interventions tailored to their development stages. However, most existing interventions primarily focus on early childhood, leaving adolescents relatively underserved.
View Article and Find Full Text PDFSchizophr Res
September 2025
UHC Sestre Milosrdnice, Department of Psychiatry, Zagreb, Croatia; Catholic University of Croatia, School of Medicine, Zagreb, Croatia.
Objective: Thalamic abnormalities have been associated with clinical and cognitive symptoms of schizophrenia, yet their role in the early stages of the disorder remain unclear. This study aimed to examine and compare thalamic perfusion differences between first-episode schizophrenia (FES) and early-course schizophrenia (ECS), along with their associations with cognitive performance and symptom severity.
Methods: This study included 100 unmedicated schizophrenia patients aged 19-30: 50 FES and 50 ECS (<5 years, ≥2 episodes).